That is why inhibition of the BET-histone interaction has recently gained increasing interest for the treatment of cancers characterized by altered histone acetylation and altered gene transcription, such as c-myc-dependent hematological malignancies and hematological malignancies with epigenetic alterations [149]. Here, MYC is linked to hematologic disorder.